These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15819141)

  • 21. Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.
    Filaković P; Laufer D; Radanović-Grgurić L; Koić O; Fijacko M; Durković M
    Psychiatr Danub; 2005 Jun; 17(1-2):63-6. PubMed ID: 16395845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
    Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D
    Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.
    Akerele E; Levin FR
    Am J Addict; 2007; 16(4):260-8. PubMed ID: 17661193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
    Karagianis JL; Dunayevich E
    J Clin Psychiatry; 2005 Jan; 66(1):137; author reply 138. PubMed ID: 15669904
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone].
    López-Torres E; Cobo I; Lucena MI
    Actas Esp Psiquiatr; 2007; 35(2):145-6. PubMed ID: 17401786
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
    Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
    Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism.
    Smith DA; Beier MT
    J Am Med Dir Assoc; 2004; 5(2):129-32. PubMed ID: 15008183
    [No Abstract]   [Full Text] [Related]  

  • 33. Risperidone questioned as dementia first-line treatment.
    Saxe T
    Geriatrics; 2004 Feb; 59(2):11; author reply 11-2. PubMed ID: 14989589
    [No Abstract]   [Full Text] [Related]  

  • 34. The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.
    Sultana J; Fontana A; Giorgianni F; Pasqua A; Cricelli C; Spina E; Gambassi G; Ivanovic J; Ferrajolo C; Molokhia M; Ballard C; Sharp S; Sturkenboom M; Trifirò G
    CNS Drugs; 2016 Nov; 30(11):1097-1109. PubMed ID: 27423216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
    Shah A
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):140-6. PubMed ID: 16416461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.
    Yury CA; Fisher JE
    Psychother Psychosom; 2007; 76(4):213-8. PubMed ID: 17570959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.
    Wu PL; Lane HY; Su KP
    Psychiatry Clin Neurosci; 2006 Feb; 60(1):115-6. PubMed ID: 16472369
    [No Abstract]   [Full Text] [Related]  

  • 38. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.
    Moisan J; Grégoire JP; Gaudet M; Cooper D
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):427-36. PubMed ID: 15786513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
    Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.